Mechanisms of local and non-specific defense
In protecting the macroorganism against primary and recurrent infections by respiratory pathogens, an absolute and leading role is assigned to local immunity factors. It is the mucous membranes of the respiratory tract that first encounter the viral aggression and initiate a cascade of defense reactions. The most important specific component of this barrier is virus-neutralizing secretory IgA antibodies. Together with cellular immunity factors, they effectively block the pathogen from entering the respiratory epithelial cells.
In addition to specific antibodies, non-specific body defense is of critical importance at the earliest stages. The most important factor in this link is the local production of $\alpha$-interferon. This potent cytokine inhibits viral replication inside cells and mobilizes other mucosal defense mechanisms, containing the spread of infection until a full-scale immune response is deployed.
Serum antibody dynamics and immunosuppression
Unlike the rapid local response, systemic humoral immunity engages with a noticeable delay. Serum antibodies circulating in the patient's blood in the vast majority of cases simply do not have time to play a significant protective role directly during the acute phase of the disease. The main reason lies in the rate of their production: this process proceeds much slower than the acute respiratory viral infection itself develops, peaks, and resolves.
Furthermore, a characteristic and highly dangerous feature of ARVI pathogenesis is virus-induced immunosuppression. Against the background of a viral attack, secondary immunodeficiency consistently develops in the body. This condition makes a person extremely vulnerable to secondary bacterial infections and significantly delays the process of complete functional recovery after having a cold.
Properties of post-infection immunity
Following an episode of ARVI, the patient develops specific protection, but its characteristics do not reliably protect the body for years to come. The general properties of post-infection antiviral immunity in most respiratory infections can be characterized by the following parameters:
- Unstable and short-lived: protective antibody titers and cellular memory fade rather quickly.
- Strictly strain-specific: immunity works exclusively against that specific variant (serotype) of the virus that caused the given disease episode.
The only clinically significant exception to this general rule is adenoviral infection. Following contact with an adenovirus, the human immune system forms a significantly stronger and more durable protective barrier, although it still retains its strict strain-specificity.
Causes of high morbidity rates
The main reason why adults and children regularly and repeatedly suffer from colds is not an initial weakness of the immune system, but the colossal diversity of ARVI pathogens themselves.
An enormous number of serotypes of various respiratory viruses continuously circulate in the human population. Since post-infection immunity is strictly strain-specific, each new encounter with the next viral serotype is perceived by the body as a completely new, previously unencountered threat. As a result, constant reinfections are caused by newer and newer pathogen serotypes against which the patient has not yet had time to develop defense mechanisms.
Briefly: answers to topical questions
Which types of bacteria most often act as causative agents of secondary infections against the background of viral immunosuppression?
Sources indicate that among the most significant causative agents of secondary bacterial infection in ARVI are:
- Pneumococcus (Streptococcus pneumoniae).
- Haemophilus influenzae (Haemophilus influenzae).
- Moraxella (Moraxella catarrhalis).
In pneumonia associated with influenza, likely causative agents also include staphylococcus, pneumococcus, and Haemophilus influenzae.
To remember the properties of immunity in ARVI, use the "Three U" rule: Unstable, Unduring, Uni-targeted (strictly strain-specific).
Class and exam questions
Why do serum antibodies fail to protect during the acute phase of ARVI?
They are produced too slowly and fail to reach protective concentrations in the blood before the acute phase of the disease runs its course and resolves.
Why do people fall ill with ARVI several times a year?
There is a huge number of different ARVI pathogen serotypes. Immunity to them is strictly strain-specific, so recurrent diseases (reinfections) are simply caused by other virus serotypes.
Are there any respiratory viruses that leave lasting immunity?
Yes, adenoviral infection is an exception. After the disease, stronger immunity is formed, but it still remains strictly strain-specific.
What else to study on this topic
- Mechanisms of action of virus-neutralizing secretory IgA
- Production and functions of $\alpha$-interferon in the respiratory tract
- Pathogenesis of secondary immunodeficiency in viral infection
- Antigenic diversity and classification of ARVI pathogen serotypes
- Features of immunity formation in adenoviral infection
Study the full topic in the «Microbiology» course
This is a summary. The course covers everything tested in classes and exams.
- Full study guide on "Immunity in ARVI" and 4,383 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 141 video lectures on the subject
Other topics in the section "ARVI pathogens"
Free video lessons: microbiologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.